Recognition and oxidative metabolism of cyclodipeptides by hepatic cytochrome P450

被引:15
作者
Delaforge, M [1 ]
Bouillé, C
Jaouen, M
Jankowski, CK
Lamouroux, C
Bensoussan, C
机构
[1] CEA Saclay, DSV, DRM, SPL, F-91191 Gif Sur Yvette, France
[2] Univ Paris 05, CNRS, UMR 8601, F-75270 Paris 06, France
[3] Rhodia, F-69192 St Fons, France
[4] Univ Moncton, FESR, Moncton, NB E1A 3E9, Canada
关键词
cytochrome P450 3A; amino acids; cyclopeptides; diketopiperazine; peptides; active site binding;
D O I
10.1016/S0196-9781(01)00364-3
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Possible recognition of peptide derivatives by hepatic cytochrome P450 3A has been suggested by binding and metabolism of numerous pseudopeptidic compounds such as ergot derivatives and cyclosporin. Natural linear or cyclic dipeptides containing hydrophobic amino acids produced by microorganisms and present in mammals are able to interact with the P450 active site through either iron-amine interactions (Type II) or hydrophobic Type I interactions. P450 3A from dexamethasone-treated rats or yeast-expressed P450 human 3A4 are the most potent in such interactions, which are particularly strong with peptides containing a histidyl residue. Some cyclodipeptides are rapidly transformed by rat cytochrome P450 3A to mono- or dihydroxylated metabolites, with turnovers around 3 nmoles min(-1) P450(-1). Linear peptides are poorly transformed in these conditions. This metabolism of cyclodipeptides occurs in 8 species including man. Such interactions and metabolism have only minor consequences in terms of P450 3A binding and metabolism of classical P450 3A substrates. These data reinforce the concept that, in addition to their effect on the regulation of P450 neosynthesis. naturally occurring endogenous peptides are also substrates of P450 3A. The physiological activities of these peptides may be modulated by their metabolism. (C) 2001 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:557 / 565
页数:9
相关论文
共 25 条
[1]  
COMBALBERT J, 1989, DRUG METAB DISPOS, V17, P197
[2]   Metabolism of tentoxin by hepatic cytochrome P-450 3A isozymes [J].
Delaforge, M ;
Andre, F ;
Jaouen, M ;
Dolgos, H ;
Benech, H ;
Gomis, JM ;
Noel, JP ;
Cavelier, F ;
Verducci, J ;
Aubagnac, JL ;
Liebermann, B .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1997, 250 (01) :150-157
[3]   A new biological contribution of cyclo(His-Pro) to the peripheral inhibition of pancreatic secretion [J].
Fragner, P ;
Presset, O ;
Bernad, N ;
Martinez, J ;
Roze, C ;
Aratan-Spire, S .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 1997, 273 (06) :E1127-E1132
[4]   New diketopiperazines from the sponge Dysidea chlorea [J].
Fu, X ;
Ferreira, MLG ;
Schmitz, FJ ;
Kelly-Borges, M .
JOURNAL OF NATURAL PRODUCTS, 1998, 61 (10) :1226-1231
[5]   INACTIVATION OF KEY METABOLIC ENZYMES BY MIXED-FUNCTION OXIDATION REACTIONS - POSSIBLE IMPLICATION IN PROTEIN-TURNOVER AND AGING [J].
FUCCI, L ;
OLIVER, CN ;
COON, MJ ;
STADTMAN, ER .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1983, 80 (06) :1521-1525
[6]   The major metabolite of dipeptide piracetam analogue GVS-111 in rat brain and its similarity to endogenous neuropeptide cyclo-L-prolylglycine [J].
Gudasheva, TA ;
Boyko, SS ;
Ostrovskaya, RU ;
Voronina, TA ;
Akparov, VK ;
Trofimov, SS ;
Rozantsev, GG ;
Skoldinov, AP ;
Zherdev, VP ;
Seredenin, SB .
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 1997, 22 (03) :245-252
[7]  
Guengerich FP, 1995, CYTOCHROME P, P473
[8]   Elucidation of distinct ligand binding sites for cytochrome P450 3A4 [J].
Hosea, NA ;
Miller, GP ;
Guengerich, FP .
BIOCHEMISTRY, 2000, 39 (20) :5929-5939
[9]   (-)-phenylahistin: A new mammalian cell cycle inhibitor produced by Aspergillus ustus [J].
Kanoh, K ;
Kohno, S ;
Asari, T ;
Harada, T ;
Katada, J ;
Muramatsu, M ;
Kawashima, H ;
Sekiya, H ;
Uno, I .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1997, 7 (22) :2847-2852
[10]  
LOWRY OH, 1951, J BIOL CHEM, V193, P265